Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech To Develop Biosimilar Assets With US$300m Financing Deal

Executive Summary

Alvotech will further develop its biosimilar assets through a US$300 million financing deal that will also enable the firm to “fuel continued growth” and be used for refinancing existing debt.

You may also be interested in...



Alvotech Value Rises Again As Portion Of Debt Is Wiped Away

Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.

Alvotech Reels In Abdi Ibrahim For Access To Turkey

In a move to take its pipeline of biosimilar monoclonal antibodies global, Alvotech has struck a deal with Abdi Ibrahim that will give it localization advantages in Turkey.

Sandoz Biopharma Head Levick To Become CEO Of Alvotech

Mark Levick, Sandoz’ head of development for biopharmaceuticals, has been chosen to become CEO of Alvotech from August.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel